Efficacy and safety of tacrolimus vs. cyclophosphamide for idiopathic membranous nephropathy: A meta-analysis of Chinese adults

Abstract

The efficacy and safety of tacrolimus (TAC) and cyclophosphamide (CTX) in the treatment of idiopathic membranous nephropathy (IMN) were compared in Chinese adult patients using a meta- analysis of the available literatures. Randomized controlled clinical trials (RCTs) of the treatment of primary IMN with TAC or CTX combined with corticosteroids in the English databases PubMed, Embase and Cochrane, as well as Chinese databases, were searched. Qualified studies were subjected to quality assessment and meta-analysis. A total of 8 RCTs, including 359 Chinese patients, were included in the meta-analysis. The complete remission rate and overall remission rate in the TAC treatment group after 6 months of treatment were higher than those in the CTX treatment group. No significant difference in remission rate was found after 12 months of treatment. There was no significant difference in the adverse reaction between the two groups at the 6th or 12th months. TAC-based treatment was associated with a faster response than CTX at the 6th month, but there was no significant difference between the two groups at 12th month in Chinese adults. Further study is needed to evaluate the long-term efficacy and safety of this treatment regimen.

Keywords

idiopathic membranous nephropathy / tacrolimus / cyclophosphamide

References

[1] BeckLH, BonegioRG, LambeauG, et al. . M-type phospholipase a2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med, 2009, 361(1): 11-21 PMCID: 2762083 PMID: 19571279

[2] StanescuHC, Arcos-BurgosM, MedlarA, et al. . Risk hla-dqa1 and pla(2)r1 alleles in idiopathic membranous nephropathy. N Engl J Med, 2011, 364(7): 616-626 PMID: 21323541

[3] BullichG, BallarinJ, OliverA, et al. . HLA-DQA1 and PLA2R1 polymorphisms and risk of idiopathic membranous nephropathy. Clin J Am Soc Nephrol, 2014, 9(2): 335-343 PMCID: 3913240 PMID: 24262501

[4] J Biomed Sci, 2010, 17(1

[5] KimS, ChinHJ, NaKY, et al. . Single nucleotide polymorphisms in the phospholipase a2 receptor gene are associated with genetic susceptibility to idiopathic membranous nephropathy. Nephron Clin Pract, 2011, 1173): 253-258

[6] CoenenMJ, HofstraJM, DebiecH, et al. . Phospholipase a2 receptor (pla2r1) sequence variants in idiopathic membranous nephropathy. J Am Soc Nephrol, 2013, 24(4): 677-683 PMCID: 3609136 PMID: 23431073

[7] PonticelliC, GlassockRJ. Glomerular diseases: Membranous nephropathy—a modern view. Clin J Am Soc Nephrol, 2013, 9(3): 609-616 PMCID: 3944756 PMID: 23813556

[8] XuJ, ZhangW, XuY, et al. . Tacrolimus combined with corticosteroids in idiopathic membranous nephropathy: A randomized, prospective, controlled trial. Contrib Nephrol, 2013, 181: 152-162 PMID: 23689577

[9] LiX, LvR, HeQ, et al. . Early initiation of tacrolimus or cyclophosphamide therapy for idiopathic membranous nephropathy with severe proteinuria. J Nephrol, 2008, 21(4): 584-591 PMID: 18651550

[10] ChenW, ChenD, XuG. An observation of tacrolimus in the treatment of idiopathic membranous nephropathy. Shiyong Yixue Zazhi (Chinese), 2009, 25(10): 1674-1675

[11] LiY, WangS, ZhaoJ, et al. . Comparison of the efficacies of tacrolimus and cyclophosphamide combined with hormone in the treatment of idiopathic membranous nephropathy. Zhongguo Linchuang Yaolixue Yu Zhiliaoxue (Chinese), 2012, 17(7): 797-801

[12] LiuJ. The study on the treatment of idiopathic membranous nephropathy with tacrolimus. Graduation dissertation, 2009

[13] ChenM, LiH, LiXY, et al. . Tacrolimus combined with corticosteroids in treatment of nephrotic idiopathic membranous nephropathy: A multicenter randomized controlled trial. Am J Med Sci, 2010, 339(3): 233-238 PMID: 20220333

[14] ShenX. Clinical observation of tacrolimus in combination with low-dose glucocorticoid in treating idiopathic membranous nephropathy. Graduation dissertation, 2012

[15] HeL, PengY, LiuH, et al. . Treatment of idiopathic membranous nephropathy with combination of low-dose tacrolimus and corticosteroids. J Nephrol, 2013, 26(3): 564-571 PMID: 22956434

[16] YuanH, LiuN, SunGD, et al. . Effect of prolonged tacrolimus treatment in idiopathic membranous nephropathy with nephrotic syndrome. Pharmacology, 2013, 91(5–6): 259-266 PMID: 23652322

[17] XieG, XuJ, YeC, et al. . Immunosuppressive treatment for nephrotic idiopathic membranous nephropathy: A meta-analysis based on chinese adults. PLoS One, 2012, 7(9): 44330